Coloplast Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Kristian Villumsen

Chief executive officer

DKK 21.4m

Total compensation

CEO salary percentage	54.2%
CEO tenure	4yrs
CEO ownership	0.04%
Management average tenure	4.7yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kristian Villumsen's remuneration changed compared to Coloplast's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b
Jun 30 2017	n/a	n/a	DKK 3b
Mar 31 2017	n/a	n/a	DKK 3b
Dec 31 2016	n/a	n/a	DKK 3b
Sep 30 2016	DKK 10m	DKK 6m	DKK 3b

Compensation vs Market: Kristian's total compensation ($USD3.06M) is below average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.

CEO

Kristian Villumsen (52 yo)

4yrs

Tenure

DKK 21,400,000

Compensation

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kristian Villumsen	President & CEO	4yrs	DKK 21.40m	0.043% CHF 10.5m
Anders Lonning-Skovgaard	Executive VP & CFO	8.4yrs	DKK 10.80m	no data
Allan Rasmussen	Executive Vice President of Global Operations	8.4yrs	DKK 9.60m	0.00015% CHF 36.8k
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 9.00m	no data
Paul Marcun	Executive Vice President of Growth	3.9yrs	DKK 11.00m	no data
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000030% CHF 7.4k
Ellen Bjurgert	Vice President of Investor Relations	6.2yrs	no data	no data
Dennis Kaysen	Director of Corporate Communications	no data	no data	no data
Dorthe Ronnau	Senior Vice President of People & Culture	less than a year	no data	no data
Alain Morvan	Senior Vice President of Sales Europe	10.7yrs	no data	no data
Rasmus Møller	Senior Vice President of Wound & Skin Care	2.3yrs	no data	no data
Manu Varma	Senior Vice President of Chronic Care - North America	4.7yrs	no data	no data

4.7yrs

Average Tenure

53yo

Average Age

Experienced Management: 020259063's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Barfod	Senior Controller & Employees Representative Director	16.9yrs	DKK 450.00k	0.000030% CHF 7.4k
Carsten Hellmann	Independent Director	5yrs	DKK 690.00k	0.0028% CHF 694.2k
Lars Rasmussen	Chairman of the Board	4yrs	DKK 1.84m	0.098% CHF 24.0m
Niels Louis-Hansen	Deputy Chairman	54.9yrs	DKK 938.00k	21.14% CHF 5.2b
Marianne Wiinholt	Independent Director	2yrs	DKK 880.00k	0.00024% CHF 58.9k
Jette Nygaard-Andersen	Independent Director	7yrs	DKK 600.00k	no data
Nikolaj Gundersen	Employees Representative Director	4.9yrs	DKK 450.00k	0% CHF 0
Roland Pedersen	Employees Representative Director	4.9yrs	DKK 450.00k	0.00070% CHF 171.7k
Annette Bruls	Independent Director	less than a year	DKK 497.00k	no data

4.9yrs

Average Tenure

57yo

Average Age

Experienced Board: 020259063's board of directors are considered experienced (4.9 years average tenure).

Coloplast Management

Management criteria checks 4/4

Key information

Recent management updates

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Less than half of directors are independent

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

First quarter 2021 earnings released

Revenue beats expectations

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age